Unexpected Bone Formation Produced by RANKL Blockade

Publication date: Available online 19 July 2017
Source:Trends in Endocrinology & Metabolism
Author(s): Sergio Portal-Núñez, Aranzazu Mediero, Pedro Esbrit, Olga Sánchez-Pernaute, Raquel Largo, Gabriel Herrero-Beaumont
Denosumab (Dmab) is a humanized monoclonal antibody that blocks RANKL (receptor activator for nuclear factor κB ligand), thereby exerting a potent bone antiresorptive action. Dmab treatment leads to a dramatic and sustained increase in bone mass through mechanisms that are currently under debate. It is also a matter of controversy whether this potent action of Dmab could lead to intrabone dystrophic mineralization. Recent research has uncovered a possible anabolic role of Dmab involving RANKL-dependent reverse signaling in osteoblasts, and that bone marrow adipocytes can modulate osteoclastogenesis through the production of RANKL. We comment here on potential pathways which might account for the anabolic action of Dmab. The impact of this proposed mechanism needs to be addressed in further research.



http://ift.tt/2uasX2v